Kelvin J. Y

Oct 12, 2024 | pubs.acs.org | Junzhe Xiao |Andrew Myers |Kelvin J. Y |Richard Porter

Introduction and BackgroundClick to copy section linkSection link copied!The lincosamide antibiotics inhibit bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, near the peptidyl transferase center. (1) The last lincosamide antibiotic to receive FDA approval for human use was clindamycin, in 1970, but after more than 50 years of use in hospitals and the community, bacterial resistance to clindamycin is now widespread.